Synergy Pharma's (SGYP) Phase 3 Trial of Plecanatide in Patients with CIC Meets Primary Endpoint
Tweet Send to a Friend
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced positive top-line results from the second of two pivotal phase 3 clinical trials ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE